Abstract
The objective of this retrospective analysis was the evaluation of direct/medical costs of immunosuppressive treatment with tacrolimus (FK 506) and cyclosporin A in liver transplantation. The analysis was based on data from the german centers of a pan-European clinical trial where all given drugs as well as all serious events, graft reactions and the number of transplantations were documented. The costs of the treatment with tacrolimus were DM 158,276 per patient; those for cyclosporin A were DM 176,392. The main reason for the difference was the amount and types of drugs administered. The direct costs per surviving patient were in the tacrolimus group DM 192,314 (20 of 113 patients) and in the cyclosporin A group DM 227,669 (25 of 111 patients). The cost-effectiveness ratio for tacrolimus is about 15.5% better than for cyclosporin A.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.